As a result, targeting CCR8+ Treg cells through anti-CCR8 mAb or anti-CCL1 neutralizing mAb provides an opportunity for the selective depletion of Treg cells as an immunotherapeutic approach for the treatment of breast cancer. This evidence concerns the gene CCL1 and breast cancer.